Energy, Cognition & Mood
Best Peptides for Anxiety & Stress: Clinical Evidence (2026)
A clinical, evidence-graded look at the four peptides marketed for anxiety and stress — Selank, N-Acetyl Selank Amidate, Semax and DSIP — separating the single human anxiety trial from preclinical and marketing claims.
SelankSemaxDSIPanxiolytic peptidesevidence-graded
The quick verdict
An honest, evidence-graded ranking of the four peptides marketed for anxiety and stress — and why only Selank has a real human anxiety trial.
- Best overall
- Selank — The only peptide with a published human anxiety trial — comparable to a benzodiazepine in GAD/neurasthenia without sedation or dependence (Grade B).
- Best value
- Selank — Also the best-evidenced choice for the cost; the cheaper-sounding alternatives (NA-Selank, DSIP) have no human anxiety data to justify them.
- Best for Calm without sedation (the benzodiazepine alternative people seek)
- Selank — Its human signal specifically pairs anxiolysis with the absence of sedation, cognitive dulling, dependence and withdrawal.
How we evaluated
We ranked each peptide strictly by the strength of human evidence for anxiety or stress as a measured endpoint — not fame, mechanism elegance, or evidence for other conditions. Human trials outrank animal data, which outrank in-vitro and mechanism-only reasoning; anecdote and vendor copy do not count. Evidence grades follow PeptideVox's A-to-D ramp (A = human RCT/meta; B = lower-tier human; C = preclinical only; D = anecdotal/marketing).
- Human anxiety evidence. Whether any published human study used an anxiety or stress endpoint in an actual patient or stressed population.
- Evidence quality. Trial size, controls, region/language diversity, and whether effect sizes were actually reported.
- Mechanistic coherence. Whether a plausible, ideally human-observed mechanism (e.g. enkephalin stabilization, indirect GABAergic tone) supports the claim.
- Safety & fit. Tolerability for an anxiety indication specifically — e.g. sedation vs stimulation, dependence risk, and uncharacterized long-term data.
- Regulatory honesty. FDA approval/compounding status and WADA exposure, stated plainly rather than glossed over.
Rating scale: 1-5 stars reflecting human-evidence strength for anxiety: 5 = robust human RCT data; 1 = mechanism/marketing only. Star ratings track the per-item evidence grade.
Last verified .
At a glance
| # | Name | Evidence | Rating | Best for | Pricing |
|---|---|---|---|---|---|
| 1 | Selank | B | 3.5 | Those seeking the single best-evidenced peptide for anxiety — calm without sedation | Research chemical / not FDA-approved; not a sourcing recommendation |
| 2 | N-Acetyl Selank Amidate | D | 1.5 | Illustrating how marketing outruns evidence — not for anyone seeking proof | Research chemical / not FDA-approved; not a sourcing recommendation |
| 3 | Semax | C | 2.0 | Stroke/cognition research interest — not anxiety, where its profile is a mismatch | Research chemical / not FDA-approved; not a sourcing recommendation |
| 4 | DSIP (Delta sleep-inducing peptide) | C | 1.5 | Sleep-research curiosity — not a defensible anxiety or stress choice | Research chemical / not FDA-approved; not a sourcing recommendation |
Selank
The only peptide with a real human anxiety trial
Selank is the clear evidence leader and the only peptide in this category with a published human trial in an actual anxiety population. The pivotal study was a Russian comparative trial in 62 patients (Selank n=30 versus the benzodiazepine medazepam n=32) with generalized anxiety disorder and neurasthenia, using Hamilton, Zung and CGI scales plus serum enkephalin assays. Anxiolytic efficacy was similar to medazepam, but Selank additionally produced antiasthenic and mild psychostimulant effects and — critically — no sedation, no cognitive impairment, and no dependence or withdrawal. The same trial documented its enkephalin mechanism in patients: baseline Leu-enkephalin half-life was reduced and correlated with symptom severity, then rose during treatment. A human fMRI study adds a plausible amygdala-connectivity correlate, and rodent work shows Selank potentiated diazepam's effect under chronic mild stress. It is graded B rather than A because the human dataset is small, single-region and largely Russian-language, with no large independent placebo-controlled Western RCT or meta-analysis, and the abstract reports comparable efficacy only qualitatively without published effect sizes.
Strengths
- Only peptide here with a published human anxiety trial (GAD/neurasthenia)
- Anxiolysis comparable to a benzodiazepine without sedation, dependence or withdrawal
- Enkephalin mechanism observed in the patients themselves, not just animals
- Supported by a human fMRI amygdala-connectivity signal
Weaknesses
- Only Grade B: small, single-country, Russian-language, no Western placebo-controlled RCT or meta-analysis
- Effect sizes not published in the abstract; figures circulating online should be treated cautiously
- Near-absent long-term and repeated-course safety data; not FDA-approved
- Best for
- Those seeking the single best-evidenced peptide for anxiety — calm without sedation
- Pricing
- Research chemical / not FDA-approved; not a sourcing recommendation
Source: Zozulia et al., Zh Nevrol Psikhiatr 2008 (PMID 18454096)
N-Acetyl Selank Amidate
A stabilized Selank analog with zero dedicated studies
N-Acetyl Selank Amidate (NA-Selank) is Selank with two extra terminal modifications — an N-terminal acetyl cap and a C-terminal amide — intended to slow enzymatic breakdown and extend duration. The problem is that no human study has ever been performed on this modified compound, and neither has any living-animal study or measured pharmacokinetic work. Every benefit claimed for it is extrapolated from parent Selank purely by structural analogy. The marketing-versus-data gap is wide: acetylation plus amidation is a chemically sound stabilization strategy in principle, but specific vendor claims of a 200-to-300-minute half-life, two-to-five-times Selank potency, or better blood-brain-barrier penetration appear only in vendor and SEO copy with no primary citation. Terminal caps could preserve, enhance, or subtly alter target engagement — and that has never been tested. It ranks second here only because its parent scaffold is the one peptide with real human anxiety data; on its own merits, for anxiety specifically, it is Grade D, unproven. Do not assume Selank's human anxiety results transfer to this chemically altered analog, and do not let the longer name imply a stronger product.
Strengths
- Built on the Selank scaffold, the one peptide here with genuine human anxiety data
- Acetylation plus amidation is a chemically rational stabilization strategy in principle
- If the modification preserves activity, it could in theory extend duration
Weaknesses
- Zero dedicated human or animal studies, and no measured pharmacokinetics
- Half-life and potency multipliers trace only to vendor copy with no primary source
- Toxicology, adverse-event and interaction data are entirely absent
- Best for
- Illustrating how marketing outruns evidence — not for anyone seeking proof
- Pricing
- Research chemical / not FDA-approved; not a sourcing recommendation
Source: SelfDecode Drugs / Tydes 2024 (no NA-Selank studies)
Semax
Real human pedigree, wrong indication
Semax is a credible research peptide with genuine human data — but almost all of it is for acute ischemic stroke recovery and cognition, not anxiety. Small Russian placebo-controlled trials and a Russian-literature meta-analysis support faster neurological recovery and raised plasma BDNF after stroke, and small human studies suggest attention and short-term-memory effects that expert reviewers judged limited and methodologically weak. The shared human fMRI study showed amygdala-connectivity changes, but no human trial has ever used an anxiety or mood endpoint. The entire basis for Semax's anxiety and mood reputation is rodent data showing antidepressant- and anxiolytic-like effects and attenuation of chronic-stress behavior via BDNF/TrkB upregulation and monoamine activation — animal-only, hence Grade C for anxiety. An important caveat for anxious users: Semax is mildly stimulating, with clinical-observation reports of mild stimulation or even anxiety at higher doses, plus sleep disturbance if dosed late. A peptide that can increase anxiety at higher doses is a poor first choice for an anxiety indication. It is better thought of as a stroke and cognition peptide than an anxiolytic, and it is one of the peptides on the pending July 2026 FDA compounding review agenda — but for cerebral ischemia, not anxiety.
Strengths
- Genuine human clinical data (for stroke recovery and, weakly, cognition)
- Coherent rodent mechanism via BDNF/TrkB and monoamine activation
- On the FDA's July 2026 compounding review agenda (for non-anxiety indications)
Weaknesses
- No human trial has ever used an anxiety or mood endpoint — anxiolytic claim is animal-only
- Mildly stimulating; can be anxiogenic at higher doses, a poor fit for anxiety
- Can disturb sleep if dosed late in the day
- Best for
- Stroke/cognition research interest — not anxiety, where its profile is a mismatch
- Pricing
- Research chemical / not FDA-approved; not a sourcing recommendation
DSIP (Delta sleep-inducing peptide)
A sleep peptide whose stress claim was refuted
Delta sleep-inducing peptide is included because it is heavily marketed for stress — but it is fundamentally a sleep peptide, and its specific stress mechanism failed when actually tested in humans. DSIP's only credible human evidence is two tiny double-blind crossover sleep trials from 1981 (roughly six subjects each) showing a modest, non-sedating sleep-normalizing effect. For stress specifically, the one controlled human test of its HPA and cortisol claim was negative: intravenous DSIP did not affect CRH-induced or meal-induced ACTH and cortisol in healthy men. There is no human anxiety trial at all. In-vitro GABA-enhancing and NMDA-blunting interactions provide a calming rationale, but after roughly fifty years no DSIP receptor, gene or precursor has been identified, and one major review called it a still-unresolved riddle. A paradoxical signal is worth noting: used as an anesthesia adjunct, DSIP unexpectedly increased heart rate and reduced anesthetic depth rather than calming — an odd finding for any compound positioned as a relaxant. To the extent better sleep helps stress, any benefit would be indirect. For anxiety or stress as a measured endpoint it is the weakest case in this group, grading C to D.
Strengths
- Modest, non-sedating sleep-normalizing signal in two small human crossover trials
- In-vitro GABA-enhancing and NMDA-blunting activity offers a calming rationale
- Better sleep could indirectly help stress in some people
Weaknesses
- Its direct cortisol/stress claim was tested in humans and refuted
- No human anxiety trial; no identified receptor, gene or precursor after ~50 years
- Paradoxically increased heart rate as an anesthesia adjunct
- Best for
- Sleep-research curiosity — not a defensible anxiety or stress choice
- Pricing
- Research chemical / not FDA-approved; not a sourcing recommendation
Source: Spath-Schwalbe et al., Psychoneuroendocrinology 1995 (PMID 7777652)
Feature comparison
| Feature | Selank | N-Acetyl Selank Amidate | Semax | DSIP (Delta sleep-inducing peptide) |
|---|---|---|---|---|
| Human anxiety trial | ✓ | — | — | — |
| Evidence grade (anxiety) | B | D | C | C-D |
| Anxiety endpoint studied | ✓ | — | — | — |
| Feature | Selank | N-Acetyl Selank Amidate | Semax | DSIP (Delta sleep-inducing peptide) |
|---|---|---|---|---|
| Non-sedating | ✓ | Unknown | Mildly stimulating | Non-sedating (sleep peptide) |
| Feature | Selank | N-Acetyl Selank Amidate | Semax | DSIP (Delta sleep-inducing peptide) |
|---|---|---|---|---|
| FDA compounding review 2026 | — | — | Yes (non-anxiety) | Yes (non-anxiety) |
| WADA exposure (S0) | Prohibited (catch-all) | Prohibited (catch-all) | Prohibited (catch-all) | Prohibited (catch-all) |
Frequently asked
Which peptide has the best evidence for anxiety?
Selank, by a wide margin. It is the only one of the four with a published human trial in an actual anxiety population — a 62-patient Russian comparative study in generalized anxiety disorder and neurasthenia, where intranasal Selank matched the benzodiazepine medazepam for anxiolytic efficacy but without sedation, cognitive dulling, dependence or withdrawal. The same trial documented a plausible enkephalin mechanism in patients. Even so, this is still only a Grade B signal: the dataset is small, single-region and largely Russian-language, with no large independent placebo-controlled Western RCT or meta-analysis. Selank is not FDA-approved and is sold only as a research chemical. The other three peptides have no human anxiety trial at all.
Is Selank as good as Xanax or other benzodiazepines?
One small Russian trial reported anxiolytic efficacy comparable to medazepam, with the meaningful advantage of no sedation, cognitive dulling, dependence or withdrawal. But comparable in one small trial is not the same as proven equivalent. There is no large, independent, placebo-controlled head-to-head against modern benzodiazepines, and the English abstract did not publish scale deltas, p-values or responder percentages, so the precise effect sizes circulating online should be treated cautiously. Benzodiazepines, for all their downsides, carry decades of regulated clinical data that Selank simply lacks. Treat the comparison as genuinely promising but unsettled, and never as a basis for swapping a prescribed medication on your own.
Is N-Acetyl Selank Amidate stronger or longer-lasting than regular Selank?
There is no evidence for this. N-Acetyl Selank Amidate is Selank with an N-terminal acetyl cap and a C-terminal amide, intended to slow enzymatic breakdown, but the analog has zero dedicated human or animal studies and no measured pharmacokinetics. The widely repeated claims of a 200-to-300-minute half-life, two-to-five-times potency, or better blood-brain-barrier penetration trace only to vendor and SEO copy with no primary citation. Acetylation plus amidation is a chemically sound stabilization strategy in principle, but terminal caps could preserve, enhance, or subtly alter target engagement — and that has never been tested. For anxiety specifically it grades D, unproven. Do not assume the parent's human anxiety results transfer to this altered molecule.
Can I combine these peptides with my anxiety medication?
This is exactly the kind of decision that requires a physician, not an article. Selank potentiated the anxiolytic effect of diazepam in animal models, suggesting plausible additive effects with benzodiazepines, alcohol or other sedatives in humans — though human interaction data are absent. DSIP has opioidergic and glutamatergic activity, so additive sedative or opioid interactions are plausible but unstudied, and it showed a paradoxical heart-rate signal under anesthesia. Semax potentiates amphetamine-stimulated dopamine release in animals, suggesting theoretical caution with stimulants. For all four peptides, no formal human drug-interaction studies exist. Do not combine unapproved peptides with prescribed central-nervous-system medication without direct medical supervision.
Are these peptides legal and are they safe long-term?
In the United States all four are sold only as research chemicals labeled not for human consumption, and none is FDA-approved for anxiety or anything else. In April 2026 the FDA removed twelve peptides — including Semax and DSIP, but not Selank — from interim 503A Category 2, which lifts a prohibition flag but does not authorize compounding; a Pharmacy Compounding Advisory Committee review on July 23-24, 2026 covers non-anxiety indications. Long-term and repeated-course safety is essentially uncharacterized for all of them, and research-chemical supply carries real risks of impurity and mislabeling. Tested athletes should treat all four as captured by the WADA S0 catch-all and prohibited at all times.
Does DSIP actually lower cortisol and reduce stress?
No — at least not by the mechanism it is marketed on. DSIP is fundamentally a sleep peptide, and its specific stress claim, direct suppression of the HPA axis, was actually tested in humans and refuted: intravenous DSIP did not alter CRH-stimulated or meal-stimulated ACTH and cortisol in healthy men. Its only credible human evidence is two tiny 1981 crossover trials showing modest sleep normalization, not anxiety relief. After roughly fifty years of study, no DSIP receptor, gene or precursor has even been identified. To the extent better sleep helps stress, any benefit would be indirect. For anxiety or stress as a measured endpoint, DSIP is the weakest case in this group, grading C to D.